by Sandeep Lyall | Dec 22, 2017 | Blog
With official figures showing pregabalin related deaths to 111 and gabapentin related deaths to 59, the Home Office launched on 13th November three options for the reclassification of these two drugs. The options for its reclassification includes schedule 3, this...
by Sandeep Lyall | Sep 19, 2017 | Brexit, NHS
The full impact of Brexit may not be known for years to come, but it is clear the implications it has for healthcare in the UK and Europe. A survey of EU doctors by BMA found 42% of EU doctors admitted to considering leaving the UK as a result of the Brexit vote. The...
by Sandeep Lyall | Aug 31, 2017 | Blog, Consultancy, Pharmacist, Regulation
Should cosmetic procedures like Dermal fillers be allowed to be performed on patients, without the patient knowing if the person performing it was qualified to do so. Nuffield Council on Bioethics reported on Cosmetic Procedures: Ethical Issues stated, “there is...
by Sandeep Lyall | Aug 31, 2017 | Blog, Community Pharmacy, Regulation
Controversial from the start, prescription charges were introduced in 1952, abolished in 1965 and then reintroduced in 1968 with a system of exemptions that persists in modified form today. The charge itself has risen from 20p in 1979 to the current price of £8.60 per...
by Sandeep Lyall | Aug 31, 2017 | Blog, Regulation, Uncategorized
The US Food and Drug Administration gets drugs to the market faster than other major regulators but it is still too slow. Can approvals be achieved quicker without affecting patient safety? Companies can take years to submit their...
